Federal contract award
HHSO100201700026C
ELTROMBOPAG: A MEDICAL COUNTERMEASURE TO MITIGATE THROMBOCYTOPENIA FOLLOWING MYELOSUPPRESSIVE DOSES OF RADIATIONSEE STATEMENT OF WORK FOR MORE DETAILSIGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN92 — OTHER MEDICAL - APPLIED RESEARCH/EXPLORATORY DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $16.3M |
| Current contract value | $16.3M |
| Potential contract value / ceiling | $41.0M |
| Start date | Sep 14, 2017 |
| Current end date | May 22, 2026 |
| Potential end date | May 22, 2026 |
| Latest award activity | Jul 8, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 13 of 13 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 8, 2026 | P00013 | $-2.5M | THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE CANCELLING FUNDS IN THE AMOUNT OF $2,539,496.23 AS FOLLOWS: 1. $1,050,656.17 FROM CLIN 0013 2. $1,488,840.00 FROM CLIN 0014 3. $0.06 FROM CLIN 0012 |
| Sep 13, 2023 | P00011 | $-18.8M | THIS UNILATERAL MODIFICATION IS TO DEOBLIGATE CANCELLING FUNDS ON CLIN 00001. |
| Apr 17, 2023 | P00010 | $0 | THIS NO COST MODIFICATION IS TO CHANGE THE CONTRACTING OFFICER FROM JONATHAN GONZALEZ TO ERIN GRENINGER. ACCORDINGLY, UNDER SECTION G.1. CONTRACTING OFFICER, DELETE JONATHAN GONZALEZ AND REPLACE WITH ERIN GRENINGER. END OF MODIFICATION. |
| Nov 21, 2022 | P00009 | $0 | THE PURPOSE OF THIS UNILATERAL MODIFICATION IS TO UPDATE THE CONTRACTING OFFICER: A.) THE CONTRACTING OFFICER IS CHANGED FROM TATRICIA JAMES TO JONATHAN GONZALEZ. ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED. |
| Apr 13, 2022 | P00008 | $7.4M | REVISE CLIN 0004 |
| May 27, 2021 | P00007 | $0 | CONTRACTOR REQUESTED A NCE THROUGH 6/1/2023 DUE TO DELAYS CAUSED BY THE COVID19 PANDEMIC. |
| Sep 30, 2020 | P00006 | $2.9M | TO DEVELOP ELTROMBOPAG VIA THE ANIMAL RULE FOR THE TREATMENT OF HEMATOPOIETIC SUB-SYNDROME OF ACUTE RADIATION SYNDROME (H-ARS) DURING THE FIELD CARE PHASE OF TREATMENT TO FULFILL AND UNMET NEED IN THE CURRENT FEDERAL MEDICAL COUNTERMEASURE (MCM) PORT |
| Aug 3, 2020 | P00005 | $2.0M | TO DEVELOP ELTROMBOPAG VIA THE ANIMAL RULE FOR THE TREATMENT OF HEMATOPOIETIC SUB-SYNDROME OF ACUTE RADIATION SYNDROME (H-ARS) DURING THE FIELD CARE PHASE OF TREATMENT TO FULFILL AND UNMET NEED IN THE CURRENT FEDERAL MEDICAL COUNTERMEASURE (MCM) PORT |
| Sep 6, 2019 | P00004 | $635.8K | MOD 4 SUPPLEMENTAL FUNDING FOR ASSAY AND NON-CLINICAL STUDIES. CHANGES CO. |
| Feb 28, 2019 | 3 | $0 | ELTROMBOPAG: A MEDICAL COUNTERMEASURE TO MITIGATE THROMBOCYTOPENIA FOLLOWING MYELOSUPPRESSIVE DOSES OF RADIATION SEE STATEMENT OF WORK FOR MORE DETAILS IGF::OT::IGF |
| Apr 10, 2018 | 2 | $197.2K | ELTROMBOPAG: A MEDICAL COUNTERMEASURE TO MITIGATE THROMBOCYTOPENIA FOLLOWING MYELOSUPPRESSIVE DOSES OF RADIATION SEE STATEMENT OF WORK FOR MORE DETAILS IGF::OT::IGF |
| Jan 18, 2018 | 1 | $696.7K | ELTROMBOPAG: A MEDICAL COUNTERMEASURE TO MITIGATE THROMBOCYTOPENIA FOLLOWING MYELOSUPPRESSIVE DOSES OF RADIATION SEE STATEMENT OF WORK FOR MORE DETAILS IGF::OT::IGF |
| Sep 14, 2017 | 0 | $23.9M | ELTROMBOPAG: A MEDICAL COUNTERMEASURE TO MITIGATE THROMBOCYTOPENIA FOLLOWING MYELOSUPPRESSIVE DOSES OF RADIATIONSEE STATEMENT OF WORK FOR MORE DETAILSIGF::OT::IGF |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.